Pooled comparative analysis of transcatheter aortic valve replacement versus surgical aortic valve replacement in patients with left ventricular assist device.

IF 1.1 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS General Thoracic and Cardiovascular Surgery Pub Date : 2024-10-26 DOI:10.1007/s11748-024-02100-3
Dimitrios E Magouliotis, Grigorios Giamouzis, Thanos Athanasiou, Kyriakos Spiliopoulos, Alexandros Briasoulis, John Skoularigis, Filippos Triposkiadis, Andrew Xanthopoulos
{"title":"Pooled comparative analysis of transcatheter aortic valve replacement versus surgical aortic valve replacement in patients with left ventricular assist device.","authors":"Dimitrios E Magouliotis, Grigorios Giamouzis, Thanos Athanasiou, Kyriakos Spiliopoulos, Alexandros Briasoulis, John Skoularigis, Filippos Triposkiadis, Andrew Xanthopoulos","doi":"10.1007/s11748-024-02100-3","DOIUrl":null,"url":null,"abstract":"<p><p>A thorough literature search was conducted on patients with Left Ventricular Assist Device (LVAD) and aortic insufficiency undergoing transcatheter aortic valve replacement (TAVR). We identified all original research studies that compared the long-term outcomes of surgical transcatheter aortic valve replacement (SAVR) versus TAVR for patients with LVAD, published between 1990 and 2023. The primary endpoint was the composite of in-hospital mortality, stroke, transient ischemic attack, myocardial infarction (MI), pacemaker implantation, vascular complications and cardiac tamponade. Secondary endpoints were the median overall survival (OS), the incidence of acute kidney injury (AKI), any bleeding needing transfusions or reintervention and cost. A total of fourteen studies and 358 patients were included (TAVR: 242; SAVR: 116). The composite outcome, the incidence of AKI, the bleeding needing transfusion, along with cost were significantly higher in the SAVR group. In addition, there was no significant difference between TAVR and SAVR in terms of median OS. The median OS in the TAVR group was 18 months. Finally, the most common causes of death were progression of heart failure and pneumonia. The present meta-analysis indicates that TAVR is associated with enhanced outcomes compared to SAVR for patients with LVAD presenting aortic insufficiency. Further well-designed original studies with greater sample sizes are necessary to validate our findings.</p>","PeriodicalId":12585,"journal":{"name":"General Thoracic and Cardiovascular Surgery","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"General Thoracic and Cardiovascular Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11748-024-02100-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

A thorough literature search was conducted on patients with Left Ventricular Assist Device (LVAD) and aortic insufficiency undergoing transcatheter aortic valve replacement (TAVR). We identified all original research studies that compared the long-term outcomes of surgical transcatheter aortic valve replacement (SAVR) versus TAVR for patients with LVAD, published between 1990 and 2023. The primary endpoint was the composite of in-hospital mortality, stroke, transient ischemic attack, myocardial infarction (MI), pacemaker implantation, vascular complications and cardiac tamponade. Secondary endpoints were the median overall survival (OS), the incidence of acute kidney injury (AKI), any bleeding needing transfusions or reintervention and cost. A total of fourteen studies and 358 patients were included (TAVR: 242; SAVR: 116). The composite outcome, the incidence of AKI, the bleeding needing transfusion, along with cost were significantly higher in the SAVR group. In addition, there was no significant difference between TAVR and SAVR in terms of median OS. The median OS in the TAVR group was 18 months. Finally, the most common causes of death were progression of heart failure and pneumonia. The present meta-analysis indicates that TAVR is associated with enhanced outcomes compared to SAVR for patients with LVAD presenting aortic insufficiency. Further well-designed original studies with greater sample sizes are necessary to validate our findings.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
对使用左心室辅助装置的患者进行经导管主动脉瓣置换术与手术主动脉瓣置换术的汇总比较分析。
我们对接受经导管主动脉瓣置换术(TAVR)的左室辅助装置(LVAD)和主动脉瓣关闭不全患者进行了全面的文献检索。我们确定了 1990 年至 2023 年间发表的所有原始研究,这些研究比较了 LVAD 患者接受经导管主动脉瓣置换术(SAVR)与经导管主动脉瓣置换术(TAVR)的长期疗效。主要终点是院内死亡率、中风、短暂性脑缺血发作、心肌梗死(MI)、起搏器植入、血管并发症和心脏填塞的复合终点。次要终点是中位总生存期(OS)、急性肾损伤(AKI)发生率、任何需要输血或再次干预的出血以及费用。共纳入了 14 项研究和 358 例患者(TAVR:242 例;SAVR:116 例)。SAVR组的综合结果、AKI发生率、需要输血的出血量以及费用均明显高于TAVR组。此外,TAVR 和 SAVR 在中位 OS 方面没有明显差异。TAVR组的中位OS为18个月。最后,最常见的死亡原因是心力衰竭和肺炎。本荟萃分析表明,对于出现主动脉瓣功能不全的 LVAD 患者,与 SAVR 相比,TAVR 的疗效更好。为了验证我们的研究结果,有必要进一步开展设计合理、样本量更大的原创性研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
General Thoracic and Cardiovascular Surgery
General Thoracic and Cardiovascular Surgery Medicine-Pulmonary and Respiratory Medicine
CiteScore
2.70
自引率
8.30%
发文量
142
期刊介绍: The General Thoracic and Cardiovascular Surgery is the official publication of The Japanese Association for Thoracic Surgery and The Japanese Association for Chest Surgery, the affiliated journal of The Japanese Society for Cardiovascular Surgery, that publishes clinical and experimental studies in fields related to thoracic and cardiovascular surgery.
期刊最新文献
Postoperative pulmonary function of patients with lung cancer and interstitial lung abnormalities. Lessons from short chest drain management for primary spontaneous pneumothorax. Long-term results of the frozen elephant trunk technique in primary chronic type B aortic dissection. A balanced mitral leaflet and large ring strategy avoids systolic anterior motion in Barlow's disease. Preoperative neutrophil-to-lymphocyte ratio predicts recurrence of esophageal squamous cell carcinoma after neoadjuvant triplet chemotherapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1